# Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

> **NCT07494435** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Haichang Biotech Co., Ltd.** · enrollment: 230 (estimated)

## Conditions studied

- Hepato Cellular Carcinoma (HCC)
- Renal Cell Cancer

## Interventions

- **DRUG:** WGI-0301
- **DRUG:** Nivolumab (240 mg)
- **DRUG:** WGI-0301

## Key facts

- **NCT ID:** NCT07494435
- **Lead sponsor:** Zhejiang Haichang Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07494435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07494435, "Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07494435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*